Generic Name and Formulations:
Buprenorphine (as HCl), naloxone (as HCl dihydrate); 0.7mg/0.18mg, 1.4mg/0.36mg, 2.9mg/0.71mg, 5.7mg/1.4mg, 8.6mg/2.1mg, 11.4mg/2.9mg; sublingual tabs; menthol-flavor.
Orexo U.S., Inc.
Indications for ZUBSOLV:
Treatment of opioid dependence, as part of a complete treatment plan including counseling and psychosocial support.
Dissolve under tongue; do not cut, chew or swallow. Place additional tabs sublingually in different places under the tongue at the same time if needed. Start when clear signs of withdrawal occur; individualize based on type and degree of opioid dependence. Induction (under supervision): Day 1: Initially 1.4mg/0.36mg; give the remainder of the Day 1 dose up to 4.2mg/1.08mg in divided doses (1 or 2 tabs of 1.4mg/0.36mg) at 1.5–2hr intervals; up to max 5.7mg/1.4mg. Day 2: a single daily dose of up to 11.4mg/2.9mg. Dependent on heroin or short-acting opioids: initiate induction with either Zubsolv or buprenorphine monotherapy (SL tabs) at least 6hrs after last opioid dose. Dependent on methadone or long-acting opioids: initiate induction with buprenorphine monotherapy (SL tabs), then transition to once-daily Zubsolv. Maintenance target dose: 11.4mg/2.9mg once daily; adjust in increments/decrements of 2.9mg/0.71mg or lower to hold treatment level; usual range 2.9mg/0.71mg–17.2mg/4.2mg once daily. Switching between Zubsolv and other buprenorphine/naloxone products: may need dose adjustments; monitor for over- or under-dosing. Switching between Suboxone SL tabs and Zubsolv: see full labeling. Concomitant use or discontinuation of CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling).
Risk of significant respiratory depression; monitor. Compromised respiratory function (eg, COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, pre-existing respiratory depression). Abuse potential (monitor). Accidental exposure may cause fatal overdose (esp. in children). Adrenal insufficiency. Obtain LFTs at baseline then monitor periodically; evaluate if hepatic event is suspected. Opioid-naïve. Elevated CSF pressure (eg, head injury, intracranial lesions). Biliary tract dysfunction. Acute abdomen. CNS depression. Hepatic impairment (severe): not recommended; (moderate): avoid use for induction. Drug abusers. Reevaluate periodically. Avoid abrupt cessation. Elderly. Labor & delivery: may need additional analgesia. Pregnancy/postpartum: may need dose adjustments; monitor closely for withdrawal. Potential neonatal opioid withdrawal syndrome during prolonged use. Nursing mothers: monitor infants.
Opioid (partial agonist-antagonist) + opioid antagonist.
Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); manage concomitant use as clinically appropriate and closely monitor. During or within 14 days of MAOIs: not recommended. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Concomitant NNRTIs (eg, efavirenz, nevirapine, etravirine, delavirdine) or PIs (eg, atazanavir with/without ritonavir): monitor and reduce Zubsolv dose, if needed. Potentiated by CYP3A4 inhibitors (eg, macrolides, azole antifungals, protease inhibitors). Antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin). May antagonize diuretics; monitor. Paralytic ileus may occur with anticholinergics.
Headache, nausea, vomiting, hyperhidrosis, constipation, signs/symptoms of withdrawal, insomnia, pain, peripheral edema; respiratory depression, orthostatic hypotension, hepatitis, hypersensitivity reactions.
SL tabs—3x10 (per carton)
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd